summary
Introduced
05/25/2022
05/25/2022
In Committee
05/25/2022
05/25/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
AI Summary
This bill, the Biologics Market Transparency Act of 2022, amends the Federal Food, Drug, and Cosmetic Act to require holders of approved applications for biological products to promptly report the marketing status of their products. It expands the reporting requirements to include holders of biological product applications approved under the Public Health Service Act, in addition to holders of drug applications approved under the Federal Food, Drug, and Cosmetic Act. The bill also requires a one-time report from all biological product application holders on the availability of their products, and allows the Secretary to identify discontinued products in the "Purple Book" list of licensed biological products, while removing products with revoked or suspended licenses.
Committee Categories
Health and Social Services
Sponsors (4)
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) (on 05/25/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/senate-bill/4302/all-info |
| BillText | https://www.congress.gov/117/bills/s4302/BILLS-117s4302is.pdf |
| Bill | https://www.congress.gov/117/bills/s4302/BILLS-117s4302is.pdf.pdf |
Loading...